한국어

내부자 거래

EDGAR

Immunome, Inc.

이사, 임원 및 10% 이상 주주가 SEC 양식 3, 4, 5로 보고한 거래이며, 각 제출 문서의 XML에서 읽었습니다. 코드와 그 설명은 SEC의 원문입니다.

양식 4는 거래 후 영업일 2일 이내에 제출해야 하므로 가장 최근 거래는 아직 제출되지 않았을 수 있습니다.

기간: 2025년 11월 15일 이후 날짜의 거래.

공개시장 매수(코드 P): 거래 8건, 84,018주; 주식 수 × 주당 가격의 합계: 1,761,718.29
공개시장 매도(코드 S): 거래 23건, 1,089,210주; 주식 수 × 주당 가격의 합계: 24,543,680.48

합계는 나열된 제출 거래를 더한 것이며, 보고된 내용을 센 것일 뿐 방향을 나타내지 않습니다.

73건 중 1–50건 표시

SEC 양식 3, 4, 5에 제출된 내부자 거래(최신순)
날짜	보고자	코드	취득 또는 처분	주식 수	주당 가격(제출된 대로)	가치(산출)	거래 후 보유 주식 수	직접 또는 간접	규칙 10b5-1 체크란	주석	출처
2026년 9월 11일 2026년 9월 15일 제출	Higgins Jack Officer: Chief Scientific Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	18,000	1.35	24,300 산출: 주식 수 × 주당 가격. 정확한 값 24300.00.	78,250	직접(D)	예	—	제출 문서 열기 0001993684-26-000008 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 9월 11일 2026년 9월 15일 제출	Higgins Jack Officer: Chief Scientific Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	13,200	25.32	334,224 산출: 주식 수 × 주당 가격. 정확한 값 334224.00.	65,050	직접(D)	예	F1 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.	제출 문서 열기 0001993684-26-000008 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 9월 11일 2026년 9월 15일 제출	Higgins Jack Officer: Chief Scientific Officer	G Bona fide gift Common Stock	처분(D)	8,800	0	—	56,250	직접(D)	예	—	제출 문서 열기 0001993684-26-000008 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 9월 11일 2026년 9월 15일 제출	Higgins Jack Officer: Chief Scientific Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (18,000) — 행사가 1.35	취득(A)	18,000	0	—	133,840	직접(D)	예	F3 F3 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001993684-26-000008 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 12일 2026년 8월 12일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	11,048	27.25	301,058 산출: 주식 수 × 주당 가격. 정확한 값 301058.00.	92,211	직접(D)	예	F5 F5 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.	제출 문서 열기 0001808343-26-000010 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 11일 2026년 8월 12일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	62,291	26.23	1,633,892.93 산출: 주식 수 × 주당 가격. 정확한 값 1633892.93.	0	간접(I) See footnote	예	F1, F4, F3 F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026. F4 The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000010 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 10일 2026년 8월 12일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	10,125	26.07	263,958.75 산출: 주식 수 × 주당 가격. 정확한 값 263958.75.	62,291	간접(I) See footnote	예	F1, F2, F3 F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026. F2 The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000010 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 7일 2026년 8월 10일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	15,248	26.06	397,362.88 산출: 주식 수 × 주당 가격. 정확한 값 397362.88.	72,416	간접(I) See footnote	예	F1, F4, F3 F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026. F4 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000009 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 6일 2026년 8월 10일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	20,840	26.06	543,090.4 산출: 주식 수 × 주당 가격. 정확한 값 543090.40.	87,664	간접(I) See footnote	예	F1, F2, F3 F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026. F2 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000009 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 4일 2026년 8월 6일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	50,366	12.92	650,728.72 산출: 주식 수 × 주당 가격. 정확한 값 650728.72.	50,366	직접(D)	예	—	제출 문서 열기 0001831215-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 4일 2026년 8월 6일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	40,250	10.60	426,650 산출: 주식 수 × 주당 가격. 정확한 값 426650.00.	90,616	직접(D)	예	—	제출 문서 열기 0001831215-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 4일 2026년 8월 6일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	90,616	25.09	2,273,555.44 산출: 주식 수 × 주당 가격. 정확한 값 2273555.44.	0	직접(D)	예	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.	제출 문서 열기 0001831215-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 4일 2026년 8월 6일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (50,366) — 행사가 12.92	처분(D)	50,366	0	—	78,542	직접(D)	예	F3 F3 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.	제출 문서 열기 0001831215-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 8월 4일 2026년 8월 6일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (40,250) — 행사가 10.60	처분(D)	40,250	0	—	120,750	직접(D)	예	F4 F4 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.	제출 문서 열기 0001831215-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	38,250	0	—	43,805	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001831144-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (76,500) — 행사가 22.01	취득(A)	76,500	0	—	76,500	직접(D)	아니요	F2 F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001831144-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Tsai Philip Officer: Chief Technical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	38,250	0	—	81,550	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0002026600-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Tsai Philip Officer: Chief Technical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (76,500) — 행사가 22.01	취득(A)	76,500	0	—	76,500	직접(D)	아니요	F2 F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0002026600-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	31,250	0	—	31,250	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001831215-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (62,500) — 행사가 22.01	취득(A)	62,500	0	—	62,500	직접(D)	아니요	F2 F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001831215-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Rosett Max Officer: Chief Financial Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	47,250	0	—	101,287	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001994071-26-000006 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Rosett Max Officer: Chief Financial Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (94,500) — 행사가 22.01	취득(A)	94,500	0	—	94,500	직접(D)	아니요	F2 F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001994071-26-000006 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Lechleider Robert Officer: Chief Medical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	54,000	0	—	69,805	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001997584-26-000006 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Lechleider Robert Officer: Chief Medical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (108,000) — 행사가 22.01	취득(A)	108,000	0	—	108,000	직접(D)	아니요	F2 F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001997584-26-000006 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	SIEGALL CLAY B Director · Officer: President and CEO	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	180,000	0	—	870,704	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001167496-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	SIEGALL CLAY B Director · Officer: President and CEO	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (360,000) — 행사가 22.01	취득(A)	360,000	0	—	360,000	직접(D)	아니요	F2 F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001167496-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Higgins Jack Officer: Chief Scientific Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	취득(A)	38,250	0	—	60,250	직접(D)	아니요	F1 F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001993684-26-000006 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 23일 2026년 7월 27일 제출	Higgins Jack Officer: Chief Scientific Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (76,500) — 행사가 22.01	취득(A)	76,500	0	—	76,500	직접(D)	아니요	F3 F3 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.	제출 문서 열기 0001993684-26-000006 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 7일 2026년 7월 9일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	1,092	12.92	14,108.64 산출: 주식 수 × 주당 가격. 정확한 값 14108.64.	1,092	직접(D)	예	—	제출 문서 열기 0001831215-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 7일 2026년 7월 9일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	1,092	25	27,300 산출: 주식 수 × 주당 가격. 정확한 값 27300.	0	직접(D)	예	F1 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.	제출 문서 열기 0001831215-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 7일 2026년 7월 9일 제출	Horn Kinney Officer: CHIEF BUSINESS OFFICER	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (1,092) — 행사가 12.92	처분(D)	1,092	0	—	128,908	직접(D)	예	F2 F2 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.	제출 문서 열기 0001831215-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 7일 2026년 7월 7일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	16,906	24.20	409,125.2 산출: 주식 수 × 주당 가격. 정확한 값 409125.20.	108,504	간접(I) See footnote	예	F1, F4, F3 F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026. F4 The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000007 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 6일 2026년 7월 7일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	83,094	24.11	2,003,396.34 산출: 주식 수 × 주당 가격. 정확한 값 2003396.34.	125,410	간접(I) See footnote	예	F1, F2, F3 F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026. F2 The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000007 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 7일 제출	Lechleider Robert Officer: Chief Medical Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	55,000	8.73	480,150 산출: 주식 수 × 주당 가격. 정확한 값 480150.00.	70,805	직접(D)	예	—	제출 문서 열기 0001997584-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 7일 제출	Lechleider Robert Officer: Chief Medical Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	22,714	21.95	498,572.3 산출: 주식 수 × 주당 가격. 정확한 값 498572.30.	48,091	직접(D)	예	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. F2 The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.	제출 문서 열기 0001997584-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 7일 제출	Lechleider Robert Officer: Chief Medical Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	16,214	22.76	369,030.64 산출: 주식 수 × 주당 가격. 정확한 값 369030.64.	31,877	직접(D)	예	F1, F3 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. F3 The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.	제출 문서 열기 0001997584-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 7일 제출	Lechleider Robert Officer: Chief Medical Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	16,072	23.44	376,727.68 산출: 주식 수 × 주당 가격. 정확한 값 376727.68.	15,805	직접(D)	예	F1, F4 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. F4 The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.	제출 문서 열기 0001997584-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 7일 제출	Lechleider Robert Officer: Chief Medical Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (55,000) — 행사가 8.73	처분(D)	55,000	0	—	290,000	직접(D)	예	F5 F5 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.	제출 문서 열기 0001997584-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 2일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	75,665	22.35	1,691,112.75 산출: 주식 수 × 주당 가격. 정확한 값 1691112.75.	232,839	간접(I) See footnote	예	F1, F6, F7 F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026. F6 The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 7월 2일 2026년 7월 2일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	24,335	23.33	567,735.55 산출: 주식 수 × 주당 가격. 정확한 값 567735.55.	208,504	간접(I) See footnote	예	F1, F8, F7 F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026. F8 The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 30일 2026년 7월 2일 제출	Barchas Isaac Director	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	101,050	21.12	2,134,176 산출: 주식 수 × 주당 가격. 정확한 값 2134176.00.	308,504	간접(I) See footnotes	예	F1, F2, F3, F4, F5 F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026. F2 The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B. F3 The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F4 The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC (ABV II) and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock. F5 The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.	제출 문서 열기 0001808343-26-000005 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 25일 2026년 6월 29일 제출	Lechleider Robert Officer: Chief Medical Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	55,000	8.73	480,150 산출: 주식 수 × 주당 가격. 정확한 값 480150.00.	70,805	직접(D)	예	—	제출 문서 열기 0001997584-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 25일 2026년 6월 29일 제출	Lechleider Robert Officer: Chief Medical Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	40,580	19.56	793,744.8 산출: 주식 수 × 주당 가격. 정확한 값 793744.80.	30,225	직접(D)	예	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. F2 The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.	제출 문서 열기 0001997584-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 25일 2026년 6월 29일 제출	Lechleider Robert Officer: Chief Medical Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	14,420	20.66	297,917.2 산출: 주식 수 × 주당 가격. 정확한 값 297917.20.	15,805	직접(D)	예	F1, F3 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. F3 The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.	제출 문서 열기 0001997584-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 25일 2026년 6월 29일 제출	Lechleider Robert Officer: Chief Medical Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Employee Stock Option (right to buy) — 기초자산 Common Stock (55,000) — 행사가 8.73	처분(D)	55,000	0	—	345,000	직접(D)	예	F4 F4 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.	제출 문서 열기 0001997584-26-000002 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 15일 2026년 6월 17일 제출	Rosett Max Officer: Chief Financial Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	취득(A)	60,000	1.05	63,000 산출: 주식 수 × 주당 가격. 정확한 값 63000.00.	114,037	직접(D)	예	—	제출 문서 열기 0001994071-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 15일 2026년 6월 17일 제출	Rosett Max Officer: Chief Financial Officer	S Open market or private sale of non-derivative or derivative security Common Stock	처분(D)	60,000	18.23	1,093,800 산출: 주식 수 × 주당 가격. 정확한 값 1093800.00.	54,037	직접(D)	예	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. F2 The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.	제출 문서 열기 0001994071-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 15일 2026년 6월 17일 제출	Rosett Max Officer: Chief Financial Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 파생증권: Stock Option (right to buy) — 기초자산 Common Stock (60,000) — 행사가 1.05	처분(D)	60,000	0	—	0	직접(D)	예	F3 F3 The option is fully vested.	제출 문서 열기 0001994071-26-000004 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 10일 2026년 6월 12일 제출	WAGENHEIM PHILIP Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Director Stock Option (right to buy) — 기초자산 Common Stock (9,897) — 행사가 18.16	취득(A)	9,897	0	—	9,897	직접(D)	아니요	F1 F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.	제출 문서 열기 0001405684-26-000003 제출 문서의 XML에서 읽음 이 행에 이의 제기
2026년 6월 10일 2026년 6월 12일 제출	BIENAIME JEAN JACQUES Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) 파생증권: Director Stock Option (right to buy) — 기초자산 Common Stock (9,897) — 행사가 18.16	취득(A)	9,897	0	—	9,897	직접(D)	아니요	F1 F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.	제출 문서 열기 0001221590-26-000018 제출 문서의 XML에서 읽음 이 행에 이의 제기

기관 보유자(양식 13F)

저장소에 이 발행사로 연결된 양식 13F 보유 내역이 없습니다. 아직 연결되지 않았거나 제출하지 않은 보유자는 0이 아니라 없는 것입니다.

5% 보유자(스케줄 13D, 13G)

SEC 구조화 형식(2024년 말 이후)으로 제출된 스케줄을 여기서 읽습니다. 이전 스케줄은 자유 텍스트여서 읽지 않습니다.

5% 보유자, 최신 사건순, 제출된 대로
보유자	해당 종류 대비 비율	보유 주식 수	사건일	양식	출처
Vanguard Capital Management Common Stock	5.04	5,725,578	09/30/2026 2026년 10월 30일 제출	SCHEDULE 13G	제출 문서 열기 0002100119-26-001633 이 행에 이의 제기
T. Rowe Price Investment Management, Inc. COMMON STOCK	17.4	19,676,883	06/30/2026 2026년 8월 14일 제출	SCHEDULE 13G/A정정 2	제출 문서 열기 0001897612-26-000609 이 행에 이의 제기
Sirenia Capital Management LP Common Stock, par value $0.0001 per share	4.3	4,832,279.00	06/30/2026 2026년 8월 14일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000919574-26-005205 이 행에 이의 제기
Alex Silverstein Common Stock, par value $0.0001 per share	4.3	4,832,279.00	06/30/2026 2026년 8월 14일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000919574-26-005205 이 행에 이의 제기
Sirenia Capital Management LP Common Stock, par value $0.0001 per share	6.1	6,895,000.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G	제출 문서 열기 0000919574-26-003222 이 행에 이의 제기
Alex Silverstein Common Stock, par value $0.0001 per share	6.1	6,895,000.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G	제출 문서 열기 0000919574-26-003222 이 행에 이의 제기
T. Rowe Price Investment Management, Inc. COMMON STOCK	14.5	16,364,011	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0001897612-26-000495 이 행에 이의 제기
Redmile Group, LLC Common Stock, $0.0001 par value per share	4.9	5,558,885.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G/A정정 4	제출 문서 열기 0001104659-26-062570 이 행에 이의 제기
Jeremy C. Green Common Stock, $0.0001 par value per share	4.9	5,558,885.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G/A정정 4	제출 문서 열기 0001104659-26-062570 이 행에 이의 제기
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share	0	0.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000919574-26-003480 이 행에 이의 제기
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share	0	0.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000919574-26-003480 이 행에 이의 제기
Steven A. Cohen Common Stock, par value $0.0001 per share	0	0.00	03/31/2026 2026년 5월 15일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000919574-26-003480 이 행에 이의 제기
Enavate Sciences GP, LLC Common Stock, par value $0.0001 per share	4.3	4,768,583.00	12/18/2025 2025년 12월 22일 제출	SCHEDULE 13D/A정정 2	제출 문서 열기 0001953107-25-000019 이 행에 이의 제기
Immunome Aggregator, LP Common Stock, par value $0.0001 per share	4.3	4,768,583.00	12/18/2025 2025년 12월 22일 제출	SCHEDULE 13D/A정정 2	제출 문서 열기 0001953107-25-000019 이 행에 이의 제기
T. Rowe Price Investment Management, Inc. COMMON STOCK	12.2	10,644,674	10/31/2025 2025년 11월 7일 제출	SCHEDULE 13G	제출 문서 열기 0001897612-25-000510 이 행에 이의 제기
FMR LLC COMMON STOCK	15.0	13,056,709.11	09/30/2025 2025년 10월 7일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000315066-25-002307 이 행에 이의 제기
Abigail P. Johnson COMMON STOCK	15.0	13,056,709.11	09/30/2025 2025년 10월 7일 제출	SCHEDULE 13G/A정정 1	제출 문서 열기 0000315066-25-002307 이 행에 이의 제기
FMR LLC COMMON STOCK	7.1	6,167,666.00	06/30/2025 2025년 8월 6일 제출	SCHEDULE 13G	제출 문서 열기 0000315066-25-002061 이 행에 이의 제기
Abigail P. Johnson COMMON STOCK	7.1	6,167,666.00	06/30/2025 2025년 8월 6일 제출	SCHEDULE 13G	제출 문서 열기 0000315066-25-002061 이 행에 이의 제기
The Vanguard Group Common Stock	5.20	4,524,952	06/30/2025 2025년 7월 29일 제출	SCHEDULE 13G	제출 문서 열기 0000932471-25-000844 이 행에 이의 제기

비율은 제출 문서가 지정한 종류에 대한 것이며 보유자가 밝힌 그대로입니다. 그룹 구성원은 각자 그룹의 주식을 보고하므로 행을 합산하지 않습니다.

읽은 내용

2004년 6월 14일부터 2026년 11월 13일까지의 제출 문서 1,873,745건을 읽음: 양식 3, 3/A, 4, 4/A, 5, 5/A.

아카이브를 아직 읽는 중이라 일부 연도는 불완전할 수 있습니다. 여기서 제출 수가 적은 해가 실제로 적게 제출되었다는 뜻은 아닙니다.

제출 연도별 읽은 문서
제출 연도	읽은 문서
2015	1
2016	204,322
2017	202,494
2018	202,048
2019	193,638
2020	144,184
2021	224,474
2022	40,015
2023	199,811
2024	84,357
2025	235,518
2026	137,107

SEC가 XML을 요구하기 전의 제출 문서는 목록에만 있고 내용은 추출하지 않습니다.

Immunome, Inc.(으)로 돌아가기